- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2011 (2011), Article ID 594809, 7 pages
The Role of Cytokine in the Lupus Nephritis
1Department of Disease Control and Homeostasis, School of Medicine, College of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-8641, Japan
2Division of Blood Purification, Kanazawa University Hospital, Kanazawa, Japan
3Department of Laboratory Sciences, School of Medicine, College of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan
Received 26 May 2011; Accepted 12 August 2011
Academic Editor: Brian Poole
Copyright © 2011 Yasunori Iwata et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- A. S. Bomback and G. B. Appel, “Updates on the treatment of lupus nephritis,” Journal of the American Society of Nephrology, vol. 21, no. 12, pp. 2028–2035, 2010.
- H. Yokoyama, T. Wada, A. Hara et al., “The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese,” Kidney International, vol. 66, no. 6, pp. 2382–2388, 2004.
- V. R. Kelley, “Leukocyte-renal epithelial cell interactions regulate lupus nephritis,” Seminars in Nephrology, vol. 27, no. 1, pp. 59–68, 2007.
- D. Perry, A. Sang, Y. Yin, Y. Y. Zheng, and L. Morel, “Murine models of systemic lupus erythematosus,” Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 271694, 19 pages, 2011.
- C. Gómez-Guerrero, P. Hernández-Vargas, O. López-Franco, G. Ortiz-Muñoz, and J. Egido, “Mesangial cells and glomerular inflammation: from the pathogenesis to novel therapeutic approaches,” Current Drug Targets, vol. 4, no. 3, pp. 341–351, 2005.
- S. Yung, R. C. W. Tsang, J. K. H. Leung, and T. M. Chan, “Increased mesangial cell hyaluronan expression in lupus nephritis is mediated by anti-DNA antibody-induced IL-1β,” Kidney International, vol. 69, no. 2, pp. 272–280, 2006.
- S. Yung, Q. Zhang, Z. Z. Chen, W. C. Kwok, L. L. Sing, and M. C. Tak, “Anti-DNA antibody induction of protein kinase C phosphorylation and fibronectin synthesis in human and murine lupus and the effect of mycophenolic acid,” Arthritis and Rheumatism, vol. 60, no. 7, pp. 2071–2082, 2009.
- C. Gordon, G. E. Ranges, J. S. Greenspan, and D. Wofsy, “Chronic therapy with recombinant tumor necrosis factor-α in autoimmune NZB/NZW F1 mice,” Clinical Immunology and Immunopathology, vol. 52, no. 3, pp. 421–434, 1989.
- C. Gordon and D. Wofsy, “Effects of recombinant murine tumor necrosis factor-α on immune function,” Journal of Immunology, vol. 144, no. 5, pp. 1753–1758, 1990.
- D. Kontoyiannis and G. Kollias, “Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor,” European Journal of Immunology, vol. 30, no. 7, pp. 2038–2047, 2000.
- N. Jacob, H. Yang, L. Pricop et al., “Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway,” Journal of Immunology, vol. 182, no. 4, pp. 2532–2541, 2009.
- C. K. Edwards III, T. Zhou, J. Zhang et al., “Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-Ipr/Ipr mice by a transcriptional inhibitor of TNF-α,” Journal of Immunology, vol. 157, no. 4, pp. 1758–1772, 1996.
- Y. Deguchi and S. Kishimoto, “Tumour necrosis factor/cachectin plays a key role in autoimmune pulmonary inflammation in lupus-prone mice,” Clinical and Experimental Immunology, vol. 85, no. 3, pp. 392–395, 1991.
- T. Wada, T. Naito, R. C. Griffiths, T. M. Coffman, and V. R. Kelley, “Systemic autoimmune nephritogenic components induce CSF-1 and TNF-α in MRL kidneys,” Kidney International, vol. 52, no. 4, pp. 934–941, 1997.
- T. Wada, A. Schwarting, M. S. Chesnutt, D. Wofsy, and V. R. Kelly, “Nephritogenic cytokines and disease in MRL-Faslpr kidneys are dependent on multiple T-cell subsets,” Kidney International, vol. 59, no. 2, pp. 565–578, 2001.
- X. Su, T. Zhou, P. Yang, C. K. Edwards, and J. D. Mountz, “Reduction of arthritis and pneumonitis in motheaten mice by soluble tumor necrosis factor receptor,” Arthritis and Rheumatism, vol. 41, no. 1, pp. 139–149, 1998.
- R. Segal, M. Dayan, H. Zinger, and E. Mozes, “Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFα monoclonal antibody and by pentoxiphylline,” Lupus, vol. 10, no. 1, pp. 23–31, 2001.
- A. Rahman and D. A. Isenberg, “Systemic lupus erythematosus,” The New England Journal of Medicine, vol. 358, no. 9, pp. 929–939, 2008.
- H. Yokoyama, M Takaeda, T. Wada, et al., “Glomerular ICAM-1 expression related to circulating TNF-α in human glomerulonephritis,” Nephron, vol. 76, no. 4, pp. 425–433, 1997.
- M. Aringer and J. S. Smolen, “The role of tumor necrosis factor-alpha in systemic lupus erythematosus,” Arthritis Research and Therapy, vol. 10, no. 1, article 202, 2008.
- R. Matsumura, K. Umemiya, T. Sugiyama et al., “Anti-tumor necrosis factor therapy in patients with difficult-to-treat lupus nephritis: a prospective series of nine patients,” Clinical and Experimental Rheumatology, vol. 27, no. 3, pp. 416–421, 2009.
- M. De Bandt, J. Sibilia, X. Le Loët et al., “Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey,” Arthritis Research & Therapy., vol. 7, no. 3, pp. R545–551, 2005.
- M. B. Stokes, K. Foster, G. S. Markowitz et al., “Development of glomerulonephritis during anti-TNF-alpha; therapy for rheumatoid arthritis,” Nephrology Dialysis Transplantation, vol. 20, no. 7, pp. 1400–1406, 2005.
- B. Liang, D. B. Gardner, D. E. Griswold, P. J. Bugelski, and X. Y. R. Song, “Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus,” Immunology, vol. 119, no. 3, pp. 296–305, 2006.
- B. A. Kiberd, “Interleukin-6 receptor blockage ameliorates murine lupus nephritis,” Journal of the American Society of Nephrology, vol. 4, no. 1, pp. 58–61, 1993.
- B. Ryffel, B. D. Car, H. Gunn, D. Roman, P. Hiestand, and M. J. Mihatsch, “Interleukin-6 exacerbates glomerulonephritis in (NZB × NZW)F1 mice,” American Journal of Pathology, vol. 144, no. 5, pp. 927–937, 1994.
- H. B. Richards, M. Satoh, M. Shaw, C. Libert, V. Poli, and W. H. Reeves, “Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus,” Journal of Experimental Medicine, vol. 188, no. 5, pp. 985–990, 1998.
- S. Wan, C. Xia, and L. Morel, “IL-6 produced by dendritic cells from lupus-prone mice inhibits CD4+ CD25+ T cell regulatory functions,” Journal of Immunology, vol. 178, no. 1, pp. 271–279, 2007.
- Y. Nishitani, A. Kubo, M. Iwano et al., “Imbalance between interleukin-6 and adrenomedullin mRNA levels in peripheral blood mononuclear cells of patients with lupus nephritis,” Clinical and Experimental Immunology, vol. 124, no. 2, pp. 330–336, 2001.
- G. G. Illei, Y. Shirota, C. H. Yarboro et al., “Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study,” Arthritis and Rheumatism, vol. 62, no. 2, pp. 542–552, 2010.
- J. F. McHale, O. A. Harari, D. Marshall, and D. O. Haskard, “TNF-α and IL-1 sequentially induce endothelial ICAM-1 and VCAM-1 expression in MRL/lpr lupus-prone mice,” Journal of Immunology, vol. 163, no. 7, pp. 3993–4000, 1999.
- T. V. Lebedeva and A. K. Singh, “Increased responsiveness of B cells in the murine MRL/Lpr model of lupus nephritis to interleukin-1β,” Journal of the American Society of Nephrology, vol. 5, no. 7, pp. 1530–1534, 1995.
- T. Takemura, K. Yoshioka, K. Murakami et al., “Cellular localization of inflammatory cytokines in human glomerulonephritis,” Virchows Archiv, vol. 424, no. 5, pp. 459–464, 1994.
- B. A. Kiberd and A. W. Stadnyk, “Established murine lupus nephritis does not respond to exogenous interleukin-1 receptor antagonist; a role for the endogenous molecule?” Immunopharmacology, vol. 30, no. 2, pp. 131–137, 1995.
- Y. Iwata, T. Wada, K. Furuichi et al., “p38 mitogen-activated protein kinase contributes to autoimmune renal injury in MRL-Faslpr mice,” Journal of the American Society of Nephrology, vol. 14, no. 1, pp. 57–67, 2003.
- Y. Iwata, K. Furuichi, N. Sakai et al., “Dendritic cells contribute to autoimmune kidney injury in MRL-Fas lpr mice,” Journal of Rheumatology, vol. 36, no. 2, pp. 306–314, 2009.
- V. D. D’Agati, “Renal Disease in Systemic Lupus Erythematosus, Mixed Connective Tissue Disease, Sjögren’s Syndrome, and Rheumatoid Arthritis,” in Heptinstall’s Pathology of the Kidney, 2006.
- Z. Zhang, V. C. Kyttaris, and G. C. Tsokos, “The role of IL-23/IL-17 axis in lupus nephritis,” Journal of Immunology, vol. 183, no. 5, pp. 3160–3169, 2009.
- O. M. Steinmetz, J. E. Turner, H. J. Paust et al., “CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis,” Journal of Immunology, vol. 183, no. 7, pp. 4693–4704, 2009.
- V. C. Kyttaris, Z. Zhang, V. K. Kuchroo, M. Oukka, and G. C. Tsokos, “Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice,” Journal of Immunology, vol. 184, no. 9, pp. 4605–4609, 2010.
- Y. Wang, S. Ito, Y. Chino et al., “Laser microdissection-based analysis of cytokine balance in the kidneys of patients with lupus nephritis,” Clinical and Experimental Immunology, vol. 159, no. 1, pp. 1–10, 2010.
- J. C. Crispín and G. C. Tsokos, “Human TCR-αβ+ CD4− CD8− T cells can derive from CD8+ T cells and display an inflammatory effector phenotype,” Journal of Immunology, vol. 183, no. 7, pp. 4675–4681, 2009.
- E. Kikawada, D. M. Lenda, and V. R. Kelley, “IL-12 deficiency in MRL-Faslpr mice delays nephritis and intrarenal IFN-γ expression, and diminishes systemic pathology,” Journal of Immunology, vol. 170, no. 7, pp. 3915–3925, 2003.
- C. E. Carvalho-Pinto, M. I. García, M. Mellado et al., “Autocrine production of IFN-γ by macrophages controls their recruitment to kidney and the development of glomerulonephritis in MRL/lpr mice,” Journal of Immunology, vol. 169, no. 2, pp. 1058–1067, 2002.
- A. Schwarting, T. Wada, K. Kinoshita, G. Tesch, and V. R. Kelley, “IFN-γ receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice,” Journal of Immunology, vol. 161, no. 1, pp. 494–503, 1998.
- M. Ramanujam, P. Kahn, W. Huang et al., “Interferon-α treatment of Female (NZW × BXSB)F1 mice mimics some but not all features associated with the Yaa mutation,” Arthritis and Rheumatism, vol. 60, no. 4, pp. 1096–1101, 2009.
- Z. Liu, R. Bethunaickan, W. Huang et al., “Interferon-α accelerates murine systemic lupus erythematosus in a T cell-dependent manner,” Arthritis and Rheumatism, vol. 63, no. 1, pp. 219–229, 2011.
- H. Agrawal, N. Jacob, E. Carreras et al., “Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease,” Journal of Immunology, vol. 183, no. 9, pp. 6021–6029, 2009.
- J. D. Hron and S. L. Peng, “Type I IFN protects against murine lupus,” Journal of Immunology, vol. 173, no. 3, pp. 2134–2142, 2004.
- A. Schwarting, K. Paul, S. Tschirner et al., “Interferon-β: a therapeutic for autoimmune lupus in MRL-Fas lpr mice,” Journal of the American Society of Nephrology, vol. 16, no. 11, pp. 3264–3272, 2005.
- A. N. Theofilopoulos, R. Baccala, B. Beutler, and D. H. Kono, “Type I interferons (α/β) in immunity and autoimmunity,” Annual Review of Immunology, vol. 23, pp. 307–336, 2005.
- S. C. Satchell, O. Buchatska, S. B. Khan et al., “Interferon-β reduces proteinuria in experimental glomerulonephritis,” Journal of the American Society of Nephrology, vol. 18, no. 11, pp. 2875–2884, 2007.
- J. Faust, J. Menke, J. Kriegsmann et al., “Correlation of renal tubular epithelial cell-derived interleukin-18 up-regulation with disease activity in MRL-Faslpr mice with autoimmune lupus nephritis,” Arthritis and Rheumatism, vol. 46, no. 11, pp. 3083–3095, 2002.
- H. A. Shui, S. M. Ka, W. M. Wu et al., “LPS-evoked IL-18 expression in mesangial cells plays a role in accelerating lupus nephritis,” Rheumatology, vol. 46, no. 8, pp. 1277–1284, 2007.
- P. Bossù, D. Neumann, E. Del Giudice et al., “IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 2, pp. 14181–14186, 2003.
- G. V. Halade, M. M. Rahman, A. Bhattacharya, J. L. Barnes, B. Chandrasekar, and G. Fernandes, “Docosahexaenoic acid-enriched fish oil attenuates kidney disease and prolongs median and maximal life span of autoimmune lupus-prone mice,” Journal of Immunology, vol. 184, no. 9, pp. 5280–5286, 2010.
- K. Masutani, M. Akahoshi, K. Tsuruya et al., “Predominance of Th1 immune response in diffuse proliferative lupus nephritis,” Arthritis and Rheumatism, vol. 44, no. 9, pp. 2097–2106, 2001.
- H. Yokoyama, T. Takabatake, M. Takaeda et al., “Up-regulated MHC-class II expression and γ-IFN and soluble IL-2R in lupus nephritis,” Kidney International, vol. 42, no. 3, pp. 755–763, 1992.
- W. S. Uhm, K. Na, G. W. Song et al., “Cytokine balance in kidney tissue from lupus nephritis patients,” Rheumatology, vol. 42, no. 8, pp. 935–938, 2003.
- R. W. Y. Chan, F. M. M. Lai, E. K. M. Li et al., “Intrarenal cytokine gene expression in lupus nephritis,” Annals of the Rheumatic Diseases, vol. 66, no. 7, pp. 886–892, 2007.
- M. Tucci, C. Quatraro, L. Lombardi, C. Pellegrino, F. Dammacco, and F. Silvestris, “Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18,” Arthritis and Rheumatism, vol. 58, no. 1, pp. 251–262, 2008.
- N. Charles, D. Hardwick, E. Daugas, G. G. Illei, and J. Rivera, “Basophils and the T helper 2 environment can promote the development of lupus nephritis,” Nature Medicine, vol. 16, no. 6, pp. 701–707, 2010.
- S. V. Kaveri, L. Mouthon, and J. Bayry, “Basophils and nephritis in lupus,” The New England Journal of Medicine, vol. 363, no. 11, pp. 1080–1082, 2010.
- S. Shimizu, N. Sugiyama, K. Masutani et al., “Membranous glomerulonephritis development with Th2-type immune deviations in MRL/lpr mice deficient for IL-27 receptor (WSX-1),” Journal of Immunology, vol. 175, no. 11, pp. 7185–7192, 2005.
- M. Akahoshi, H. Nakashima, Y. Tanaka et al., “Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 42, no. 8, pp. 1644–1648, 1999.
- D. J. Huss, R. C. Winger, G. M. Cox, et al., “TGF-β signaling via smad4 drives IL-10 production in effector Th1 cells and reduces T cell trafficking in EAE,” The European Journal of Immunology, vol. 41, no. 10, pp. 2987–2996, 2011.
- A. O'Garra and P. Vieira, “TH1 cells control themselves by producing interleukin-10,” Nature Reviews Immunology, vol. 7, no. 6, pp. 425–428, 2007.
- D. Jankovic, D. G. Kugler, and A. Sher, “IL-10 production by CD4+ effector T cells: a mechanism for self-regulation,” Mucosal Immunology, vol. 3, no. 3, pp. 239–246, 2010.
- R. L. Brunsing and E. R. Prossnitz, “Induction of interleukin-10 in the T helper type 17 effector population by the G protein coupled estrogen receptor (GPER) agonist G-1,” Immunology, vol. 134, no. 1, pp. 93–106, 2011.
- H. Ishida, T. Muchamuel, S. Sakaguchi, S. Andrade, S. Menon, and M. Howard, “Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice,” Journal of Experimental Medicine, vol. 179, no. 1, pp. 305–310, 1994.
- C. T. Ravirajan, Y. Wang, L. A. Matis et al., “Effect of neutralizing antibodies to IL-10 and C5 on the renal damage caused by a pathogenic human anti-dsDNA antibody,” Rheumatology, vol. 43, no. 4, pp. 442–447, 2004.
- K. R. M. Blenman, B. Duan, Z. Xu et al., “IL-10 regulation of lupus in the NZM2410 murine model,” Laboratory Investigation, vol. 86, no. 11, pp. 1136–1148, 2006.
- L. Llorente, Y. Richaud-Patin, C. García-Padilla, et al., “Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic Lupus erythematosus,” Arthritis and Rheumatism, vol. 43, no. 8, pp. 1790–1800, 2000.